Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer

Ann Oncol. 2019 Jun 1;30(6):1019. doi: 10.1093/annonc/mdy531.
No abstract available

Publication types

  • Published Erratum